Cho BC, Abreu DR, Hussein M, Cobo M, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol 2022 May 13. pii: S1470-2045(22)00226.
PMID: 35576957